¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review - Wikidata - awgldk - TriplyDB

¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review

¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review

http://www.wikidata.org/entity/Q26823362

about

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Solitary Plasmacytoma of the Sternum Mimicking Bone Metastasis in a Patient with a History of Breast Cancer Evaluated by F-18-FDG PET/CT PET/CT in Oncology: Current Status and Perspectives.18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation.11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.The role of imaging techniques in the management of multiple myeloma.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to treatment in patients with multiple myeloma.Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.New Approaches to Molecular Imaging of Multiple Myeloma.Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma Curability of multiple myeloma.Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients.Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on 68Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods.[Hemato-oncological imaging : Importance of hybrid procedures].The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients.Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.

P2860

Q30561836-A7F97330-2918-465D-A391-4A5E9F58EFF9 Q33639416-1A2A74AD-8368-4A9F-8F3C-216A11CD78F2 Q33665109-9D9CFE56-5762-45C0-B3AB-9AD8DF261B80 Q34365686-900AF230-A086-4C27-A8C4-3F11448AEA55 Q35781619-96247739-A6EC-4421-9052-DE3551EDADAE Q36205157-9A0A186D-3E12-43B1-A866-219151A47A04 Q38033606-25B74DC8-9D6F-4ED4-ADC6-55E4A1D655A1 Q38038609-37BAE108-4C84-4E94-8E0C-9AFD3DD78F1D Q38058468-3A45232E-5C33-47EA-8622-35699F542B4D Q38248907-2FD90C0E-325C-461B-BB36-904A24EF4A68 Q38626360-09373EFC-EF5E-4359-8321-69327ECFE95F Q38805822-E7656D60-6CBE-44C2-A986-8DEFE404E8B8 Q39024142-CFC1E180-1AB0-46FD-82BE-6F8B1B8C1C37 Q39530606-20E8D66E-AA00-42BA-BA70-031B4A865215 Q41370609-F4BFF65C-7503-4F6F-8ADC-6363237A577E Q42183191-5E1BA70C-2DE6-42C4-B783-C568AFAAE578 Q42388536-CBFF4ECC-9B6D-4BEA-B452-6F79681EAA94 Q45929472-A3F47353-80D4-4236-8AC2-E18A880DCEDA Q52597352-021A6F03-6AD1-44B8-89E7-BE865668E518 Q52659368-5E2A304B-AA40-4448-A98E-7096F27C26FC Q52982170-3EE73816-8E05-4638-A096-86433257EE87 Q53072763-2BE90EA3-73F1-44A5-8676-084938B7180D Q53086997-9C822557-F41B-4975-9622-E9A6548DB874 Q53123777-C0986D9F-372B-4E02-9184-1C8F504E7988

P2860

¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review

http://www.wikidata.org/entity/Q26823362

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@ast

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@en

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@nl

type

label

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@ast

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@en

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@nl

prefLabel

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@ast

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@en

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@nl

P1433

Q26823362-F6DF3591-D5C2-48EE-B733-0F08466937A1

P1476

Q26823362-C548A097-155F-4062-938E-3C4BFF8C206E

P2093

Q26823362-387CE9B8-220C-4839-A411-CD6E205925B6

Q26823362-9DD96CFF-552B-487F-8FAE-94790E58E260

Q26823362-BFEE6FD9-F19D-4EE4-8490-088CC28EF53E

Q26823362-DF079E14-6634-48DF-B15C-8F8208CE0C12

Q26823362-E30C14E6-F28C-4479-A706-B6D53A2FC77E

Q26823362-EE5D346C-9FA1-4A53-AD9A-FB1A51C123B7

P2860

Q26823362-03CE2389-0C62-485C-867A-85BD295035AB

Q26823362-07D80990-56C8-4499-B57E-0279963F9177

Q26823362-26FC1AD9-625C-46D2-8F19-D3BB196B91DF

Q26823362-3179471F-ECBE-4C98-91B6-DC9F2F3F66C3

Q26823362-4078EFB5-FAFF-48E7-9056-46E0447561C6

Q26823362-615179CB-E32A-4925-A7AA-435ABA6E9D9B

Q26823362-6B9B627C-0551-48EB-B264-5F4DF1FD65B5

Q26823362-702BCB8E-A0A6-4CF5-8798-F0784975CCF5

Q26823362-730C6692-DE6C-4DEE-BE66-B432DDB40FED

Q26823362-85169A35-2155-4C86-BB83-49D9095DC6F6

P304

Q26823362-A335985E-7DF9-42B6-9776-0365D8E4F52C

P31

Q26823362-262B2D2D-AE65-496D-98D9-BCFF6C8228E6

Q26823362-E07EBC07-DFA7-4E5B-9EE7-EA46B6C75754

P356

Q26823362-E59BBFFC-BF4F-4932-AF36-C69817E19BDB

P407

Q26823362-CA76020C-B542-4E14-9FC6-9FECCD69B8E1

P433

Q26823362-B884F641-27B9-4C86-8088-E37F31BE0A29

P478

Q26823362-CE54DDBB-45DC-43C7-9639-492404732214

P577

Q26823362-F3869D94-6F45-4CAD-9912-BDFDD669009C

P5875

Q26823362-AC34AB4A-0366-417F-B61D-AE70098BC2B3

P698

Q26823362-92C81E97-8B95-48AB-80DF-2766134F9DC9

P356

P1433

P1476

¹⁸F-fluoro-deoxyglucose positr ...... e disease: a systematic review

@en

P2093

Danielle van Lammeren-Venema

http://www.w3.org/2001/XMLSchema#string

Ingrid I. Riphagen

http://www.w3.org/2001/XMLSchema#string

Josien C. Regelink

http://www.w3.org/2001/XMLSchema#string

Josée M. Zijlstra

http://www.w3.org/2001/XMLSchema#string

Otto S. Hoekstra

http://www.w3.org/2001/XMLSchema#string

Sonja Zweegman

http://www.w3.org/2001/XMLSchema#string

P2860

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

PET in oncology: will it replace the other modalities?

The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.

Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.

Initial results in the assessment of multiple myeloma using 18F-FDG PET.

Diagnostic utility of FDG PET in multiple myeloma.

P304

1971-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.1002/CNCR.26467

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51615222

http://www.w3.org/2001/XMLSchema#string

P698

21887677

http://www.w3.org/2001/XMLSchema#string